Ms Catalina Rosa Rodriguez, BSN, RN-BC | |
4115 Karl Rd Apt 102, Columbus, OH 43224-2070 | |
(614) 702-3212 | |
Not Available |
Full Name | Ms Catalina Rosa Rodriguez |
---|---|
Gender | Female |
Speciality | Case Manager/care Coordinator |
Location | 4115 Karl Rd Apt 102, Columbus, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1003287509 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
163WP2201X | Registered Nurse - Ambulatory Care | RN.346811 (Ohio) | Secondary |
171M00000X | Case Manager/care Coordinator | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Ms Catalina Rosa Rodriguez, BSN, RN-BC 4115 Karl Rd Apt 102, Columbus, OH 43224-2070 Ph: () - | Ms Catalina Rosa Rodriguez, BSN, RN-BC 4115 Karl Rd Apt 102, Columbus, OH 43224-2070 Ph: (614) 702-3212 |
News Archive
Advances in personalized medicine allow doctors to select the most promising drugs for certain types of malignant tumors.
HHS Secretary Kathleen Sebelius on Wednesday held two press conferences and briefed congressional lawmakers on the recent public health emergency involving swine flu, also known as the "2009 H1N1 influenza virus," CQ HealthBeat reports (Reichard, CQ HealthBeat, 4/29).
BioClinicaâ„¢, Inc.,, a global provider of clinical trial management services, today announced its acquisition of substantially all of the assets of privately held TranSenda International, LLC. Headquartered in Bellevue, WA, TranSenda is a provider of clinical trial management software (CTMS) solutions and is a Microsoft Gold Certified Partner.
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
› Verified 4 days ago